1. Home
  2. TOP vs GRDX Comparison

TOP vs GRDX Comparison

Compare TOP & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Financial Group Limited

TOP

TOP Financial Group Limited

HOLD

Current Price

$2.10

Market Cap

34.2M

Sector

Finance

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$4.16

Market Cap

39.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TOP
GRDX
Founded
2015
N/A
Country
Singapore
United Kingdom
Employees
N/A
2
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2M
39.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TOP
GRDX
Price
$2.10
$4.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
221.2K
76.2K
Earning Date
01-20-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
81.25
N/A
EPS
N/A
N/A
Revenue
$4,723,765.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
41.89
N/A
52 Week Low
$0.61
$1.87
52 Week High
$3.33
$6.93

Technical Indicators

Market Signals
Indicator
TOP
GRDX
Relative Strength Index (RSI) 77.70 44.88
Support Level $1.01 $2.01
Resistance Level N/A $5.30
Average True Range (ATR) 0.20 0.47
MACD 0.04 -0.09
Stochastic Oscillator 91.24 19.16

Price Performance

Historical Comparison
TOP
GRDX

About TOP TOP Financial Group Limited

TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: